Price$0.68-0.72 (-51.14%)
2026-01-262026-04-29
News · 26 weeks44-100%
2025-11-022026-04-26
Mix1290d
- Other5(42%)
- SEC Filings5(42%)
- Insider2(17%)
Latest news
25 items- SECSEC Form 10-K filed by Allurion Technologies Inc.10-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)
- SECAllurion Technologies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Allurion Technologies Inc.SCHEDULE 13D/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)
- SECSEC Form 8-K filed by Allurion Technologies Inc.8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)
- PRAllurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSECompany's recent FDA approval catalyzes plan to regain compliance with listing requirements of NYSE or another exchange; shares of common stock expected to continue trading on NYSE during appeal process Allurion Technologies, Inc. (the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, has received notice from the New York Stock Exchange (NYSE) that it intends to initiate delisting proceedings against Allurion after the Company was unable to demonstrate that it had regained compliance with Section 802.01B of the Listed Company Manual requiring listed companies to maintain either (i) at least $50 million in stockholders' equity or (ii) at least $50 million in total mar
- SECAllurion Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)
- PRAllurion Announces Exercise of Warrants for $3.0 Million in Gross ProceedsAllurion Technologies, Inc. (NYSE:ALUR) (the "Company" or "Allurion"), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,659,565 shares of common stock, issued by the Company on January 27, 2025 (the "January 2025 Warrants"), February 20, 2025 (the "February 2025 Warrants") and November 12, 2025 (the "November 2025 Warrants" and together with the January 2025 Warrants and the February 2025 Warrants, the "Existing Warrants"), at a reduced exercise price of $1.15 per share. The shares of common stock issuable upon exercise of the January 2025 Warra
- SECAllurion Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)
- PRAllurion Receives U.S. FDA ApprovalApproval provides Allurion with access to approximately 80 million Americans with obesity Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval (PMA) application for the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule. "Today's approval is a watershed moment for Allurion and for obesity care in the United States," said Dr. Shantanu Gaur, Founder and Chief Executive Officer. "Our goal is to deliver patients metabolically healthy weight loss by helping them lose weight, keep it off, and maintain muscle. The Allurion Smart Capsule off
- INSIDERGibbons Brendan M. decreased direct ownership by 15% to 10,408 units (SEC Form 5)5 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)
- INSIDERBuch Ojas decreased direct ownership by 17% to 10,223 units (SEC Form 5)5 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)
- PRAllurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted PricesThrough Bionut, a leader in obesity care in Argentina, Allurion Program patients will now have access to discounted Mounjaro to be used in combination with the Allurion Smart Capsule Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced a partnership with Bionut, a leader in obesity care in Argentina, and Farmastar, a local pharmacy partner with access to the official supplier of Mounjaro (tirzepatide) in Argentina, to provide patients with access to discounted Mounjaro to be used in combination with the Allurion Smart Capsule. "The obesity epidemic is growing, and patients are in need of more therapeutic options," said Romina Sapir, Di
- SECSEC Form EFFECT filed by Allurion Technologies Inc.EFFECT - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)
- SECAllurion Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)
- PRAllurion Announces Preliminary Fourth Quarter and Full-Year 2025 ResultsStrong quarter-over-quarter revenue growth with continued, substantial improvement in operating expenses and operating loss Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced preliminary, unaudited results for the fourth quarter and full year 2025. Management expects preliminary, unaudited results for the period as follows: Fourth quarter revenue of $3.3 million to $3.7 million, a 22% to 37% increase quarter-over-quarter, and full-year revenue of approximately $15 million Substantial improvement in operating expenses and operating loss quarter-over-quarter and as compared to prior year "We are pleased with our results from the
- SECSEC Form S-3 filed by Allurion Technologies Inc.S-3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)
- SECSEC Form EFFECT filed by Allurion Technologies Inc.EFFECT - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)
- SECSEC Form POS AM filed by Allurion Technologies Inc.POS AM - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)
- SECSEC Form 424B3 filed by Allurion Technologies Inc.424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)
- SECSEC Form 424B3 filed by Allurion Technologies Inc.424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)
- SECAllurion Technologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)
- INSIDERDirector Davin Michael R received a gift of 3,212 shares, sold $4,918 worth of shares (3,212 units at $1.53) and gifted 3,212 shares, decreasing direct ownership by 73% to 1,206 units (SEC Form 4)4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)
- SECSEC Form 144 filed by Allurion Technologies Inc.144 - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)
- SECSEC Form D filed by Allurion Technologies Inc.D - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)
- SECSEC Form DEFA14A filed by Allurion Technologies Inc.DEFA14A - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)
ALUR FAQ
5 questionsWhere does ALUR stock trade?
Allurion Technologies Inc. (ALUR) is listed on NYSE.What sector and industry is ALUR in?
Allurion Technologies Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about ALUR?
Allurion Technologies Inc. has had 4 recent analyst actions on file. The most recent action was from Chardan Capital Markets: Neutral on 2024-11-14. Recent price targets range from $200.00 to $500.00.What companies are similar to ALUR?
Notable peers in the same industry include SYK (Stryker Corporation), BSX (Boston Scientific Corporation), MMM (3M Company), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare ALUR side-by-side with any of them on Quantisnow.How can I track ALUR on Quantisnow?
Quantisnow aggregates Allurion Technologies Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALUR to receive live email and push alerts on every new disclosure.